Volume 3, Issue 6, June 2025 ISSN (E): 2938-3765

POST-COVID PNEUMONIA AND PULMONARY COMPLICATIONS: A STUDY OF LONG-TERM SEQUELAE AND TREATMENT METHODS IN PATIENTS RECOVERING FROM COVID-19

Ismailov Baxromiddin Zaxriddinovich
Fergana Medical Institute of Public Health
Assistant in the Department of Pediatrics

Abstract
This analysis explores the pathophysiology, clinical features, diagnostic methods, and treatment strategies for post-COVID-19 pneumonia and related pulmonary complications. Based on recent clinical data and longitudinal studies, approximately 30–40% of hospitalized COVID-19 patients experience lasting lung abnormalities beyond the acute phase. The study highlights the multifactorial nature of post-viral complications such as organizing pneumonia, pulmonary fibrosis, and chronic inflammation. Evidence shows that early anti-inflammatory treatment, pulmonary rehabilitation, and structured follow-up improve long-term outcomes. The findings emphasize the need for dedicated post-COVID care clinics and standardized treatment protocols to manage these complex conditions, offering valuable guidance for clinicians treating COVID-19 survivors with ongoing respiratory issues.

Keywords: Coronavirus, pneumonia, pulmonary fibrosis, organizing pneumonia, long coronavirus disease 2019, respiratory rehabilitation, inflammatory lung disease, respiratory, syndrome.

Introduction

Today, the global medical community continues to grapple with the far-reaching consequences of the coronavirus disease 2019 pandemic, which has fundamentally altered our understanding of viral respiratory infections and their long-term implications. The severe acute respiratory syndrome coronavirus 2 virus, first identified in late 2019, has infected hundreds of millions of individuals worldwide, leaving an unprecedented number of survivors dealing with persistent health complications. Among these complications, pulmonary sequelae represent one of the most significant and clinically challenging aspects of post-acute coronavirus disease 2019 syndrome, commonly referred to as long coronavirus disease 2019. The respiratory system serves as the primary target for severe acute respiratory syndrome coronavirus 2 infection, with the virus demonstrating particular tropism for alveolar epithelial cells and pulmonary endothelium through its interaction with angiotensin-converting enzyme 2 receptors. This initial pulmonary involvement often progresses beyond the acute infection phase, manifesting as a spectrum of persistent respiratory abnormalities that can significantly impact patient quality of life and functional capacity. Understanding these post-infectious pulmonary complications has become

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

paramount for healthcare systems worldwide as they prepare to manage an increasing population of coronavirus disease 2019 survivors with ongoing respiratory symptoms. Recent longitudinal studies have revealed that the pulmonary consequences of coronavirus disease 2019 extend far beyond the acute phase of illness, with many patients experiencing persistent symptoms and radiological abnormalities months after initial infection. These findings have necessitated a comprehensive reevaluation of post-viral pulmonary care and the development of specialized management approaches tailored to the unique characteristics of post-coronavirus disease 2019 respiratory complications.

MAIN BODY

The development of post-coronavirus disease 2019 pulmonary complications involves complex pathophysiological mechanisms that begin during the acute infection phase and persist well beyond viral clearance. The initial viral invasion triggers an exaggerated inflammatory response characterized by massive cytokine release, commonly referred to as cytokine storm syndrome. This inflammatory cascade involves multiple mediators, including interleukin-6, tumor necrosis factor-alpha, and interleukin-1 beta, which contribute to widespread alveolar damage and endothelial dysfunction. The severe acute respiratory syndrome coronavirus 2 virus demonstrates particular affinity for pneumocytes and pulmonary capillary endothelial cells, leading to direct cellular damage and subsequent activation of coagulation cascades. This prothrombotic state contributes to microthrombi formation throughout the pulmonary vasculature, resulting in ventilation-perfusion mismatch and impaired gas exchange that can persist long after viral elimination. The combination of direct viral cytotoxicity and immune-mediated tissue damage creates an environment conducive to aberrant wound healing and fibrotic tissue formation. Emerging evidence suggests that dysregulated immune responses play a central role in the transition from acute coronavirus disease 2019 pneumonia to chronic pulmonary complications. Persistent activation of myofibroblasts and excessive collagen deposition characterize the fibrotic response, which can progress to irreversible structural lung changes. Additionally, ongoing epithelial-mesenchymal transition processes contribute to progressive loss of normal lung architecture and function. The role of autoimmune mechanisms in post-coronavirus disease 2019 pulmonary complications has gained increasing recognition. Molecular mimicry between viral antigens and host tissues may trigger autoantibody production, leading to persistent inflammatory responses even after viral clearance. These autoimmune processes can perpetuate lung injury and contribute to the chronicity of respiratory symptoms observed in many survivors.

Post-coronavirus disease 2019 pulmonary complications present with a diverse spectrum of clinical manifestations that can vary significantly among patients. The most commonly reported symptoms include persistent dyspnea, chronic cough, chest pain, and exercise intolerance. These symptoms often develop insidiously and may not correlate directly with the severity of the initial acute infection, presenting significant diagnostic challenges for clinicians. Dyspnea represents the predominant symptom in post-coronavirus disease 2019 patients, affecting approximately sixty to seventy percent of individuals with persistent pulmonary complications. This breathlessness typically manifests as exertional dyspnea that significantly limits daily activities and quality of life. The pathophysiology underlying persistent dyspnea is multifactorial, involving impaired gas

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

exchange, reduced lung compliance, pulmonary vascular dysfunction, and deconditioning effects from prolonged illness. Chronic cough affects nearly half of patients with post-coronavirus disease 2019 pulmonary sequelae and can persist for months following acute infection. This cough is often dry and nonproductive, suggesting ongoing airway inflammation and hyperresponsiveness rather than infectious processes. The persistent nature of this symptom can be particularly distressing for patients and may indicate underlying organizing pneumonia or fibrotic changes. Chest pain presents in various forms among post-coronavirus disease 2019 patients, ranging from sharp, pleuritic pain to dull, aching sensations. This symptom may result from persistent pleural inflammation, intercostal muscle strain from prolonged coughing, or pericardial involvement. Careful evaluation is necessary to distinguish between pulmonary and cardiac causes of chest discomfort in these patients. Exercise intolerance represents a significant functional limitation that affects the majority of patients with post-coronavirus disease 2019 pulmonary complications. This symptom extends beyond simple deconditioning and often involves complex interactions between respiratory, cardiovascular, and metabolic systems. Formal exercise testing frequently reveals reduced peak oxygen consumption and abnormal ventilatory responses that persist for months after acute infection.

High-resolution computed tomography of the chest serves as the gold standard for evaluating post-coronavirus disease 2019 pulmonary complications, providing detailed visualization of parenchymal abnormalities and disease progression. The most characteristic findings include ground-glass opacities, organizing pneumonia patterns, fibrotic changes, and architectural distortion that can persist for months following acute infection. Ground-glass opacities represent the most common radiological abnormality in post-coronavirus disease 2019 patients, appearing as areas of increased lung attenuation without obscuration of underlying vascular markings. These opacities typically demonstrate peripheral and lower lobe predominance, reflecting the distribution pattern observed during acute infection. The persistence of ground-glass changes beyond three months post-infection suggests ongoing inflammatory processes and increased risk for developing irreversible fibrotic changes. Organizing pneumonia patterns manifest as consolidative changes with characteristic reverse halo signs or perilobular distributions. These findings indicate active inflammatory processes with granulation tissue formation within alveolar spaces and small airways. Recognition of organizing pneumonia patterns is crucial as this condition typically responds favorably to corticosteroid therapy when identified early. Fibrotic changes represent the most concerning long-term complication of post-coronavirus disease 2019 pneumonia, characterized by traction bronchiectasis, architectural distortion, and honey-combing patterns in severe cases. These irreversible structural changes can significantly impact lung function and patient prognosis. Early identification of fibrotic progression through serial imaging is essential for initiating appropriate antifibrotic therapies and preventing further deterioration. Vascular complications, including pulmonary embolism and persistent perfusion defects, can be detected through contrast-enhanced computed tomography pulmonary angiography. These findings reflect the prothrombotic state associated with coronavirus disease 2019 and may contribute to persistent dyspnea and exercise intolerance in affected patients.

The management of post-coronavirus disease 2019 pulmonary complications requires a comprehensive, multidisciplinary approach that addresses both inflammatory processes and

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

functional limitations. Current treatment strategies focus on anti-inflammatory therapies, pulmonary rehabilitation, and supportive care measures tailored to individual patient needs and disease severity. Corticosteroid therapy remains the cornerstone of treatment for patients with evidence of organizing pneumonia or persistent inflammatory changes. Prednisolone, typically initiated at doses of 0.5 to 1.0 milligrams per kilogram daily, has demonstrated significant efficacy in reducing inflammatory burden and improving radiological abnormalities. The duration of corticosteroid treatment varies based on individual response and disease progression, with most patients requiring therapy for several months with gradual tapering protocols. Antifibrotic agents, including nintedanib and pirfenidone, have shown promise in managing patients with progressive fibrotic changes. These medications target key pathways involved in fibroblast proliferation and collagen synthesis, potentially slowing or halting the progression of pulmonary fibrosis. Early initiation of antifibrotic therapy appears most beneficial, emphasizing the importance of prompt recognition and treatment of fibrotic complications. Pulmonary rehabilitation programs represent a crucial component of comprehensive post-coronavirus disease 2019 care, addressing exercise intolerance, deconditioning, and respiratory muscle weakness. These structured programs typically include supervised exercise training, breathing techniques, education, and psychological support. Studies have demonstrated significant improvements in exercise capacity, quality of life, and functional outcomes following participation in pulmonary rehabilitation programs. Oxygen supplementation may be necessary for patients with persistent hypoxemia or exercise-induced desaturation. Long-term oxygen therapy should be prescribed based on established criteria and regularly reassessed as patients may experience gradual improvement over time. Portable oxygen systems can facilitate participation in rehabilitation activities and improve exercise tolerance. Bronchodilator therapy may benefit patients with evidence of airway hyperresponsiveness or small airway dysfunction. Inhaled beta-2 agonists and anticholinergic agents can provide symptomatic relief and improve exercise tolerance in selected patients. However, the routine use of bronchodilators should be based on objective evidence of airway obstruction rather than empirical treatment.

Comprehensive long-term monitoring is essential for optimizing outcomes in patients with post-coronavirus disease 2019 pulmonary complications. Regular follow-up visits should include clinical assessment, pulmonary function testing, imaging studies, and functional capacity evaluation to track disease progression and treatment response. Pulmonary function testing provides objective measures of respiratory impairment and disease progression. Serial spirometry, lung volume measurements, and diffusion capacity assessments can detect subtle changes in lung function and guide treatment decisions. Many patients demonstrate restrictive patterns with reduced diffusion capacity, reflecting the fibrotic nature of post-coronavirus disease 2019 pulmonary complications.

Six-minute walk testing serves as a practical assessment tool for evaluating functional capacity and exercise tolerance. This simple test correlates well with quality of life measures and can track improvement following therapeutic interventions. Regular monitoring of walk distance and oxygen saturation during testing provides valuable information about disease progression and treatment efficacy. Patient-reported outcome measures, including dyspnea scales and quality of life questionnaires, provide important insights into symptom burden and functional limitations

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

from the patient perspective. These tools complement objective assessments and help guide treatment decisions and rehabilitation strategies. Mental health screening and support represent important components of comprehensive post-coronavirus disease 2019 care, as many patients experience anxiety, depression, and post-traumatic stress related to their illness experience. Integrated care approaches that address both physical and psychological aspects of recovery optimize long-term outcomes.

In conclusion, post-COVID-19 pulmonary complications pose a serious and evolving healthcare challenge. Persistent inflammation, abnormal healing, and potential autoimmune responses can lead to long-term lung damage if not addressed early. A multidisciplinary approach-including anti-inflammatory therapy, rehabilitation, and regular monitoring-is essential. Establishing specialized post-COVID clinics and developing standardized care protocols are critical for effective management. Ongoing research into biomarkers and targeted treatments will be key to improving outcomes. As knowledge grows, healthcare providers must remain alert and adapt strategies to meet the needs of this increasing patient population.

References

1. Umarovich, B. M. (2025). DEVELOPING OF VIRAL INFECTIONS IN HEMATOPOIETIC STEM-CELL TRANSPLANT (HSCT) RECIPIENTS. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 468-473.
2. Muhammadiev, S. (2025). HEMIEPIPHYSIODESIS IN PEDIATRIC ORTHOPAEDICS AS A TREATMENT OF KNEE DEFORMITIES. International Journal of Artificial Intelligence, 1(4), 225-227.
3. Pulatjonovna, U. M. (2024). METABOLITE SYNDROME AND COGNITIVE IMPAIRMENT. IMRAS, 7(6), 419-423.
4. Умарова, М., & Кодиржонов, Н. (2022). ТРОМБОЛИТИЧЕСКАЯ ТЕРАПИЯ В ЛЕЧЕНИИ ИШЕМИЧЕСКОГО ИНСУЛЬТА. Theoretical aspects in the formation of pedagogical sciences, 1(5), 218-220.
5. Умарова, М. (2021). МИГРЕН КАСАЛЛИГИ ВА УНИНГ ШОШИЛИНЧ ТЕРАПИЯСИНИ ТАКОМИЛЛАШТИРИШ. ИНТЕРНАУКА, 47, 93.
6. Хошимова, А. Ё. (2018). ВЛИЯНИЕ ЗАГРЯЗНЕНИЯ ОКРУЖАЮЩЕЙ СРЕДЫ НА ЗАБОЛЕВАЕМОСТЬ БРОНХИАЛЬНОЙ АСТМОЙ. Актуальные вопросы современной пульмонологии. Ма, 200.
7. АБДУГАНИЕВА, А. Ё., & ЮЛДАШЕВА, Х. Б. К. ЛАБОРАТОРНАЯ ДИАГНОСТИКА ПРИ COVID-19. ИНТЕРНАУКА Учредители: Общество с ограниченной ответственностью" Интернаука", 37-38.
8. Умарова, М. (2021). ИНСОМНИА ВА МЕТАБОЛИК СИНДРОМНИНГ ЎЗАРО КОМОРБИДЛИГИ МУАММОНИНГ ДОЛЗАРБЛИГИ. Интернаука, (20-7), 29-30.
9. Исмаилов, С. И., & Маматханова, Г. М. (2022). ЭЛЕКТРОННЫЙ ДОКУМЕНТООБОРОТ КАК ВАЖНЕЙШИЙ ФАКТОР ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ УПРАВЛЕНИЯ ЗДРАВООХРАНЕНИЕМ. Евразийский журнал медицинских и естественных наук, 2(8), 38-45.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

10. Erkinovich, M. B. (2023). Prevention and Modern Treatment of Fatty Embolism in Traumatological Patients. Eurasian Medical Research Periodical, 21, 158-164.
11. Abdujabborova, C. (2024). O'tkir zaharliligini aniqlash" LUPINUS AS". Universal xalqaro ilmiy jurnal, 1(9), 151-157.
12. Abdujabborova, C. (2024). PSORALEA DRUPACEAE BUNGE (PSORALEA KOSTYANKOVA OR AKKURAI) CHEMICAL COMPOSITION AND APPLICATION IN MEDICINE. B INTERNATIONAL BULLETIN OF MEDICAL SCIENCES AND CLINICAL RESEARCH (Т. 4, Выпуск 1, сс. 9–14). Zenodo.
13. Erkinovich, M. B. (2025, February). ACCUMULATION OF FLUID IN THE KNEE JOINT. In The Conference Hub (pp. 31-35).
14. Erkinovich, M. B. (2025). EFFECT OF JOINT FLUID ON JOINT ACTIVITY IN THE BODY. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(2), 256-260.
15. Maxmudovna, M. G., Qizi, S. M. I., & Xasanboyevich, X. S. (2024). VIRAL HEPATITIS DISEASE AND ITS SPREAD AMONG THE POPULATION. THE EXAMPLE OF RISHTAN DISTRICT. Eurasian Journal of Medical and Natural Sciences, 4(1-2), 118-121.
16. Mamatkhanova, G. M., & Ismailov, S. I. (2021). Optimization Of Medical Records And Implementation Of Electronic Systems In Healthcare. The American Journal of Medical Sciences and Pharmaceutical Research, 3(01), 193-198.
17. Маматханова, Г. (2021). Оптимизация медицинской учетной документации и внедрение электронных систем в здравоохранение. Общество и инновации, 2(8/S), 61-67.
18. Мурадимова, А. Р. (2019). Нейрофизиологический аспект метаболической терапии хронической церебральной ишемии. In Инновации в медицине. Материалы I международной научно-практической конференции-Махачкала, 2019.-Том. II.-232 с. (p. 192).
19. Lutfidin o'g'li, Y. B. (2025). ENDEMIK BUQOQ KASALLIGINI TA'SIRIDAN YO'LDOSH TERMINAL SO'RGICHLARDAGI QON TOMIRLARNING PATOMORFOLOGIK O'ZGARISHLARI. THEORY AND ANALYTICAL ASPECTS OF RECENT RESEARCH, 3(33), 322-325.
20. Lutfidin o'g'li, Y. B. (2025). Major Hystologic Types of Lung Cancer. Miasto Przyszłości, 57, 81-86.
21. Yusupov, B., & Xatamova, M. (2025). GIPERTIREOZ TA'SIRIDAN YO'LDOSH TERMINAL SO'RG'ICHLARDAGI QON TOMIRLARNING PATOMORFOLOGIK O'ZGARISHLARI. Modern Science and Research, 4(2), 432-437.
22. Habibullayevna, A. G., & Shavkatjon o'g'li, Q. S. (2025, February). STRUCTURE AND INTRACELLULAR ACTIVITY OF THE DNA-CONTAINING HERPES SIMPLEX VIRUS. In International Educators Conference (pp. 126-132).
23. Мурадимова, А. Р. (2019). КЛИНИКО-НЕВРОЛОГИЧЕСКИЕ ОСОБЕННОСТИ ТЕЧЕНИЯ СО-СУДИСТОЙ ЭПИЛЕПСИИ, ПРОГНОЗИРОВАНИЯ И ЛЕЧЕНИЯ. In Инновации в медицине. Материалы I международной научно-практической конференции-Махачкала, 2019.-Том. II.-232 с. (p. 178).
24. Мурадимова, А. Р. (2019). КЛИНИКО-ДИАГНОСТИЧЕСКИЕ АСПЕКТЫ И СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ СОСУДИСТОЙ ДЕМЕНЦИИ. In

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5

Инновации в медицине. Материалы I международной научно-практической конференции-Махачкала, 2019.-Том. II.-232 с. (p. 185).
25. Xojiakbarovna, K. M. (2025). SKLETAL MUSCLE RELAXANTS. PERIPHERALLY ACTING SKLETAL MUSCLE RELAXAXANTS: NEUROMUSCULAR BLOCKERS AND SYNTHETIC COMPETITIVE BLOCKERS. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 509-514.
26. Yevgenevna, S. O. (2025). PREDICTION OF PREECLAMPSIA DEVELOPMENT IN PREGNANT WOMEN WITH OVERWEIGHT AND OBESITY. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 561-568.
27. Isroilova, G. (2023). DEVELOPING THE PRINCIPLES OF STUDYING AND TREATMENT OF VAGINAL DYSBIOSIS DURING PREGNANCY. Modern Science and Research, 2(4), 52-53.
28. Юсупова, Р. Т., & Шаланкова, О. Е. (2020). РЕПРОДУКТИВНОЕ ЗДОРОВЬЕ ДЕВОЧЕК-ПОДРОСТКОВ, ПРОЖИВАЮЩИХ В УСЛОВИЯХ ФЕРГАНСКОЙ ДОЛИНЫ. In Университетская наука: взгляд в будущее (pp. 612-614).
29. Пулатова, Н. С., Йигиталиев, А. Б., & Абдурашидов, А. А. ЭПИДЕМИОЛОГИЯ РАКА ТЕЛА МАТКИ В ФЕРГАНСКОЙ ОБЛАСТИ. 1-SON, 1-JILD IYUL 2022 1-QISM, 29.
30. Эгамбердиев, Д. Э., Абдурашидов, А. А., & Эргашов, У. Ш. ПРОФИЛАКТИКА И МЕТОФИЛАКТИКА МОЧЕКАМЕННОЙ БОЛЕЗНИ.
31. Husanboy, U. (2024). ACUTE HEMORRHAGIC CYSTITIS DISEASE IN CHILDREN AND ITS DEVELOPMENT IN THE CHILD'S DODY. In International Conference on Multidisciplinary Sciences and Educational Practices (pp. 88-94).
32. Умарова, М. (2021). ИНСУЛТДАН КЕЙИНГИ ТАЛВАСА СИНДРОМИ. Интернаука, (18-5), 46-48.
33. Pattoyevich, G. A. (2025). IRON DEFICIENCY ANEMIA IN CHILDREN: EARLY DIAGNOSIS AND MODERN TREATMENT APPROACHES. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(5), 494-501.
34. Ravshanovna, R. Y., & Abduxoliq o'g'li, R. A. (2024). Clinical and Morphological Characteristics and Treatment of Gaucher Disease. Miasto Przyszłości, 49, 1407-1412.

Web of Medicine: Journal of Medicine, Practice and Nursing
webofjournals.com/index.php/5